BCL2 and neoplasm: A project from Liu et al. [111] on tumor samples (human samples and xenograft models) found that apatinib showed osteosarcoma growth due to inhibition of VEGFR2 and consequently suppressing the STAT3/Bcl-2 signalling pathway, ultimately with low Bcl-2 levels, inducing autophagy and apoptosis.